Clinical Trial Update: A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis [Phase 2]

View source ↗

Summary

Phase 2 study of laquinimod in participants with active lupus nephritis has completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• Laquinimod (laquinimod)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Lupus Nephritis | Phase 2 | Status: COMPLETED | Results posted: 2022-03-09